IL288665A - Methods for treating cancer using prmt5 inhibitors - Google Patents
Methods for treating cancer using prmt5 inhibitorsInfo
- Publication number
- IL288665A IL288665A IL288665A IL28866521A IL288665A IL 288665 A IL288665 A IL 288665A IL 288665 A IL288665 A IL 288665A IL 28866521 A IL28866521 A IL 28866521A IL 288665 A IL288665 A IL 288665A
- Authority
- IL
- Israel
- Prior art keywords
- methods
- treating cancer
- prmt5 inhibitors
- prmt5
- inhibitors
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 101150097768 prmt5 gene Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962858076P | 2019-06-06 | 2019-06-06 | |
| EP19193850 | 2019-08-27 | ||
| PCT/EP2020/065639 WO2020245365A1 (en) | 2019-06-06 | 2020-06-05 | Methods of treating cancer using prmt5 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL288665A true IL288665A (en) | 2022-02-01 |
Family
ID=70922068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL288665A IL288665A (en) | 2019-06-06 | 2021-12-05 | Methods for treating cancer using prmt5 inhibitors |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11571437B2 (enExample) |
| EP (1) | EP3980019A1 (enExample) |
| JP (1) | JP7590351B2 (enExample) |
| KR (1) | KR20220017989A (enExample) |
| CN (1) | CN113966232A (enExample) |
| AU (1) | AU2020286961A1 (enExample) |
| BR (1) | BR112021024469A2 (enExample) |
| CA (1) | CA3142825A1 (enExample) |
| IL (1) | IL288665A (enExample) |
| JO (1) | JOP20210320A1 (enExample) |
| MA (1) | MA56095A (enExample) |
| MX (1) | MX2021014944A (enExample) |
| PH (1) | PH12021552841A1 (enExample) |
| SG (1) | SG11202112439YA (enExample) |
| TW (1) | TW202112375A (enExample) |
| WO (1) | WO2020245365A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022153161A1 (en) * | 2021-01-14 | 2022-07-21 | Pfizer Inc. | Treatment of cancer using a prmt5 inhibitor |
| CN115161341B (zh) * | 2022-06-10 | 2023-07-21 | 中国人民解放军军事科学院军事医学研究院 | 一种胃窦浸润性肠型胃癌小鼠模型的构建方法与应用 |
| WO2024118943A2 (en) * | 2022-11-30 | 2024-06-06 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a prmt5 inhibitor |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4224438A (en) | 1970-07-14 | 1980-09-23 | Boehringer Mannheim Gmbh | Adenosine-5'-carboxylic acid amides |
| US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| WO2003039523A2 (en) | 2001-11-05 | 2003-05-15 | Exiqon A/S | OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES |
| US7034147B2 (en) | 2001-11-29 | 2006-04-25 | Irm Llc | Nucleoside analog libraries |
| JP2005527502A (ja) | 2002-02-19 | 2005-09-15 | シーブイ・セラピューティクス・インコーポレイテッド | Ａ１アデノシン受容体の部分的および全アゴニスト |
| US20040043959A1 (en) | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
| AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
| JPWO2005005450A1 (ja) | 2003-07-15 | 2006-08-24 | 三井化学株式会社 | 環状ビスジヌクレオチドの合成方法 |
| EP1694642A4 (en) | 2003-12-19 | 2010-10-06 | Koronis Pharmaceuticals Inc | MUTAGENIC HETEROCYCLES |
| WO2006078752A2 (en) | 2005-01-21 | 2006-07-27 | Methylgene, Inc. | Inhibitors of dna methyltransferase |
| EP2043635A2 (en) | 2006-06-29 | 2009-04-08 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US20080132525A1 (en) | 2006-12-04 | 2008-06-05 | Methylgene Inc. | Inhibitors of DNA Methyltransferase |
| AU2009298802A1 (en) | 2008-09-23 | 2010-04-08 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
| KR20120113228A (ko) | 2009-12-18 | 2012-10-12 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 베타 세포 복제 촉진 화합물 및 그 사용 방법 |
| EP2646455A4 (en) | 2010-12-03 | 2014-04-02 | Epizyme Inc | Modulators of histone methyltransferase, and methods of use thereof |
| US9145438B2 (en) | 2010-12-03 | 2015-09-29 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| JP5906253B2 (ja) | 2010-12-16 | 2016-04-20 | アッヴィ・インコーポレイテッド | 抗ウイルス性化合物 |
| EP2694524B1 (en) | 2011-04-04 | 2016-05-18 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | 2'-o-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides |
| WO2013151975A1 (en) | 2012-04-02 | 2013-10-10 | Northeastern University | Compositions and methods for the inhibition of methyltransferases |
| WO2014035140A2 (en) | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Compounds and compositions for modulating histone methyltransferase activity |
| US20140100184A1 (en) | 2012-08-31 | 2014-04-10 | Baylor College Of Medicine | Selective inhibitors of histone methyltransferase dot1l |
| CA2899363A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| DK2935222T3 (en) | 2012-12-21 | 2019-01-07 | Epizyme Inc | PRMT5 INHIBITORS AND APPLICATIONS THEREOF |
| CA2894126A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| US9745291B2 (en) | 2012-12-21 | 2017-08-29 | Epizyme, Inc. | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
| CA2942833A1 (en) * | 2013-03-15 | 2014-09-18 | Ohio State Innovation Foundation | Inhibitors of prmt5 and methods of their use |
| US10087151B2 (en) | 2014-01-09 | 2018-10-02 | The J. David Gladstone Institutes, A Testimentary Trust Established Under The Will Of J. David Gladstone | Substituted benzoxazine and related compounds |
| US20170198006A1 (en) | 2014-06-25 | 2017-07-13 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| BR112016030787B1 (pt) | 2014-07-01 | 2022-12-20 | Takeda Pharmaceutical Company Limited | Entidade química, composição farmacêutica e seu uso |
| MX2017010844A (es) | 2015-02-24 | 2017-12-07 | Pfizer | Derivados de nucleosidos sustituidos utiles como agentes anticancerosos. |
| TWI870767B (zh) | 2015-08-26 | 2025-01-21 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
| AU2017230658B2 (en) | 2016-03-10 | 2021-03-04 | Janssen Pharmaceutica Nv | Substituted nucleoside analogues for use as PRMT5 inhibitors |
| TN2019000087A1 (en) | 2016-10-03 | 2020-07-15 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| WO2018065365A1 (en) | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| TN2019000212A1 (en) | 2017-02-27 | 2021-01-07 | Janssen Pharmaceutica Nv | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor |
| US11059850B2 (en) | 2017-12-08 | 2021-07-13 | Janssen Pharmaceutica Nv | Spirobicyclic analogues |
-
2020
- 2020-06-04 TW TW109118748A patent/TW202112375A/zh unknown
- 2020-06-05 SG SG11202112439YA patent/SG11202112439YA/en unknown
- 2020-06-05 US US16/893,477 patent/US11571437B2/en active Active
- 2020-06-05 MX MX2021014944A patent/MX2021014944A/es unknown
- 2020-06-05 EP EP20729788.8A patent/EP3980019A1/en active Pending
- 2020-06-05 PH PH1/2021/552841A patent/PH12021552841A1/en unknown
- 2020-06-05 MA MA056095A patent/MA56095A/fr unknown
- 2020-06-05 WO PCT/EP2020/065639 patent/WO2020245365A1/en not_active Ceased
- 2020-06-05 JP JP2021571834A patent/JP7590351B2/ja active Active
- 2020-06-05 CA CA3142825A patent/CA3142825A1/en active Pending
- 2020-06-05 CN CN202080043244.1A patent/CN113966232A/zh active Pending
- 2020-06-05 AU AU2020286961A patent/AU2020286961A1/en not_active Abandoned
- 2020-06-05 KR KR1020227000036A patent/KR20220017989A/ko not_active Ceased
- 2020-06-05 BR BR112021024469A patent/BR112021024469A2/pt unknown
-
2021
- 2021-12-01 JO JOP/2021/0320A patent/JOP20210320A1/ar unknown
- 2021-12-05 IL IL288665A patent/IL288665A/en unknown
-
2023
- 2023-01-26 US US18/160,246 patent/US20230241087A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220017989A (ko) | 2022-02-14 |
| TW202112375A (zh) | 2021-04-01 |
| JP2022535406A (ja) | 2022-08-08 |
| JP7590351B2 (ja) | 2024-11-26 |
| CN113966232A (zh) | 2022-01-21 |
| WO2020245365A1 (en) | 2020-12-10 |
| US20200384006A1 (en) | 2020-12-10 |
| JOP20210320A1 (ar) | 2023-01-30 |
| CA3142825A1 (en) | 2020-12-10 |
| US20230241087A1 (en) | 2023-08-03 |
| SG11202112439YA (en) | 2021-12-30 |
| MX2021014944A (es) | 2022-01-24 |
| BR112021024469A2 (pt) | 2022-01-18 |
| AU2020286961A1 (en) | 2022-02-03 |
| MA56095A (fr) | 2022-04-13 |
| EP3980019A1 (en) | 2022-04-13 |
| US11571437B2 (en) | 2023-02-07 |
| PH12021552841A1 (en) | 2022-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288522A (en) | Inhibitor of egfr for cancer treatment | |
| IL315996A (en) | Cancer treatments using PRMT5 inhibitors in collaboration with MTA | |
| IL288707A (en) | Methods for using rad51 inhibitors to treat pancreatic cancer | |
| IL268430A (en) | Methods for treating cancer using hsp90 inhibitors | |
| IL283337A (en) | Methods for treating whsc1-overexpressing cancers by inhibiting setd2 | |
| IL277981A (en) | Cancer treatment methods | |
| IL288665A (en) | Methods for treating cancer using prmt5 inhibitors | |
| IL286297A (en) | Minimal residual cancer treatment methods | |
| SG11202010793UA (en) | Methods of treating cancer | |
| EP3856352A4 (en) | Methods of treatment of cancer comprising cdc7 inhibitors | |
| SG11202104296TA (en) | Methods of treating cancer with farnesyltransferase inhibitors | |
| IL281600B2 (en) | Cancer treatment methods | |
| IL287210A (en) | Preparations for the treatment of tumors | |
| IL321326A (en) | Cancer therapies using PRMT5 inhibitors collaborate with MTA | |
| IL289811A (en) | A method for treating cancer | |
| EP3758678A4 (en) | METHODS OF TREATMENT OF CANCER WITH CHK1 INHIBITORS | |
| SG11202107017TA (en) | Methods of treating cancer | |
| EP4072561A4 (en) | CANCER TREATMENT METHODS | |
| IL279591A (en) | Cancer treatment methods using combination therapy | |
| IL288003A (en) | Cancer treatment methods using chk1 inhibitors | |
| HK40072866A (en) | Methods of treating cancer using prmt5 inhibitors | |
| PT4003533T (pt) | Métodos de tratamento de cancro multifocal | |
| IL272390A (en) | Cancer treatment methods | |
| IL312332A (en) | Cancer treatment methods | |
| HK40081110A (en) | Methods of treating cancer using dkk-1-inhibitors |